A Study of LY3819469 in Participants With Impaired and Normal Renal Function

Inclusion Criteria:

• Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²)
• Men who agree to use highly effective or effective methods of contraception and womennot of childbearing potential (WNOCBP) may participate in this trial Participants with Normal Renal Function:
• Have estimated glomerular filtration rate (eGFR) determined by Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) greater than or equal to 90 milliliter per minute (mL/min) Participants with Renal Impairment:
• Severe renal impairment: Have eGFR determined by CKD-EPI of less than 30 mL/min andnot requiring dialysis
• ESRD: Participants who have been on a stable hemodialysis schedule for at least 3months prior to planned dosing

Exclusion Criteria:

• Have a history or presence of an underlying disease, or surgical, physical, medical,or psychiatric condition
• Have any abnormality in the 12-lead electrocardiogram (ECG)
• Hemoglobin less than 8 grams per deciliter (g/dL) and clinically significant anemiasymptoms
• Have known allergies to LY3819469, related compounds or any components of theformulation, or a history of significant atopy
• Have participated in any Lp(a) siRNA therapeutic clinical trial within the last 1 year